Why the study?
Does fondaparinux improve ischemic events, bleeding, and mortality compared to enoxaparin in patients with acute coronary syndromes?
Does fondaparinux improve ischemic events, bleeding, and mortality compared to enoxaparin in patients with acute coronary syndromes?
In patients with acute coronary syndromes, fondaparinux offers similar short-term ischemic protection to enoxaparin but with significantly less major bleeding and improved long-term mortality.
Answers are grounded in this paper and cite their sources.
Supports fondaparinux preference in ACS to reduce bleeding without compromising short-term ischemia; extends prior antithrombotic comparisons with long-term outcome data.
Fondaparinux is similar to enoxaparin in reducing the risk of ischemic events at nine days, but it substantially reduces major bleeding and improves long term mortality and morbidity. (ClinicalTrials.gov number, NCT00139815.).
No takes yet. Share an insight, caveat, or question.
Salim Yusuf (2006) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: